Please assess the completion status of the following clinical trial:

Trial Title: Pegylated Liposomal Doxorubicin Containing Chemotherapy in the Treatment of Older Non-Hodgkin's Lymphoma Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age 65 years and older;~* Diagnosis of Non-Hodgkin's lymphoma where therapy with CHOP plus rituximab is considered;~* Previously untreated;~* ECOG 0-2~* Adequate renal and hepatic functions;~* Cardiac ejection fraction at least 50% by MUGA. No significant cardiac abnormalities by EKG;~* Signed informed consent~Exclusion Criteria:~* CNS involvement by lymphoma;~* Hypersensitivity to study drugs;~* Active infection;~* Prior treatment with monoclonal antibodies for cancer;~* History of cardiac disease with New York Heart Association Class II or greater or clinical evidence of congestive heart failure

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).